Gilead Sciences, Inc.

“Gilead's HIV franchise is a high-quality, annuity-like cash engine generating $7-8B in annual FCF with genuine moat durability through ~2033, and lenacapavir represents a credible market-share recovery and moat-extension catalyst in both treatment and PrEP. However, the 2033 Biktarvy patent cliff creates a structural earnings transition that management must navigate via oncology reinvestment — a track record that has destroyed an estimated $8-10B+ in capital across Forty Seven, Immunomedics, and Kite. At 13.7x forward earnings and ~6% FCF yield, the stock prices in no net growth and is fairly valued, but not cheap enough to compensate for the reinvestment risk, management quality deficit, and absence of margin of safety. Lenacapavir is the key re-rating catalyst; a more attractive entry in the $100-110 range would shift the risk/reward meaningfully.”